Articles tagged with Vaccine Development
A novel nanoparticle vaccine, called spike ferritin nanoparticle (SpFN), is being tested in a Phase 1 clinical trial at WRAIR. The vaccine has shown promise in inducing potent and broad neutralizing antibody responses against SARS-CoV-2 variants.
A new model of the SARS-CoV-2 spike protein reveals potential new vaccine targets, including spots with minimal glycan shielding. The researchers identified novel sites and confirmed their vulnerability through lab experiments.
A UConn researcher has developed a successful Zika vaccine in preclinical studies using a novel platform technology. The vaccine, based on a viral vector and enhanced expression of the virus antigen, was found to mount a strong immune response and protect against Zika virus infection.
Researchers developed a tamper-proof temperature indicator to monitor mRNA vaccine storage conditions. The system can alert healthcare workers when the vaccine reaches an unsafe temperature for a certain period, ensuring effective distribution and use of the vaccine.
Researchers at WRAIR and Duke University have confirmed the effectiveness of monoclonal antibodies against malaria. The study found that certain mAbs showed promise in both culture-based and mouse infection models, suggesting distinct sites on the circumsporozoite protein can be targeted for improved vaccines.
The introduction of immunization passports may help countries reopen and revitalize their economies while reducing the spread of SARS-CoV-2. To implement these passports effectively, governments must establish secure digital immunization records and ensure adherence to international standards.
To ensure an effective global immunization strategy against COVID-19, vaccines must be produced at scale, priced affordably, and allocated globally. The authors assess the potential contribution of leading vaccines using a traffic light system, highlighting production challenges and the need for equitable distribution. Governments and ...
Two scientists urge health agencies to invest in vaccine development based on broadly neutralizing antibodies against multiple virus variants and strains. This approach could provide immunity against emerging pandemics and serve as a pan-virus solution for prevention and treatment.
A team of Chinese scientists, led by Professor Jianping Huang, developed the Global Prediction System of the COVID-19 Pandemic (GPCP) to predict the spread of the disease. The GPCP combines epidemiological data and models using advanced algorithms, achieving better results than traditional methods.
USC researchers have developed an AI-assisted method that can predict and design effective vaccines against the coronavirus in seconds, rather than months or years. The method uses machine learning to analyze potential mutations and pinpoint the best vaccine candidates, which could help combat the evolving virus.
A new DNA-based vaccine platform has been shown to induce potent immune responses in mice, generating high levels of antibodies and strong T cell responses. The vaccine was found to be immunogenic, efficiently neutralizing the SARS-CoV-2 virus after a single immunization.
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, stimulating the production of rare immune cells needed to generate broadly neutralizing antibodies. The targeted response was detected in 97 percent of participants who received the vaccine.
The COVID-19 pandemic has accelerated scientific innovation, with scientists working at record speed to develop vaccines, diagnose, and treat the virus. Despite these advances, the pandemic has also raised concerns about public trust in science, exacerbated by mixed messaging and politicization.
Researchers at the University of Sydney have developed a novel method to rapidly synthesize safe vaccines using protein-based immunization. The approach demonstrated strong immune response in mice against tuberculosis and has potential applications for respiratory diseases, including COVID-19.
Researchers at the University of Wisconsin-Madison have developed a tool to help prioritize vaccine distribution among people who share similar risks due to their jobs. The algorithm considers both age and socioeconomic status to identify those at greater risk of severe COVID-19 complications.
A new tool predicts viral escape mutations by analyzing the relationship between viruses and human immunity, as well as the structure of sentences in natural language. The algorithm achieves accurate results without prior training, identifying high-escape potential regions in SARS-CoV-2's Spike protein.
Researchers reviewed 49 studies linking stress, depression, and poor health behaviors to impaired immune response to vaccination. Improving these factors can enhance the body's response to the COVID-19 vaccine.
A new study suggests that COVID-19 vaccines may be less effective in individuals with depression, stress, loneliness, or poor health behaviors. Engaging in exercise and getting a good night's sleep before vaccination can help boost the immune response.
Researchers have identified and characterised a new strain of Leishmania parasite to form the basis of a controlled human infection model. The study aims to accelerate vaccine development for this life-threatening disease, which causes slow-to-heal skin ulcers and has no current vaccines or effective treatments.
Researchers developed a new mRNA delivery platform using ZIF-8 nanoparticles that exhibit high mRNA loading capacity, successful endosomal escape, and synergistic GSH depletion. This approach upregulates mRNA translation and improves delivery efficiency compared to existing methods.
Experts discuss microbial-based solutions to combat COVID-19, including vaccine candidates and production platforms. The webinar explores learnings from vaccine development, innovative approaches to address systemic inflammation.
A comprehensive SARS-CoV-2 animal model study has identified two potential models: Indian rhesus macaques and African baboons. The macaque model shows promise for vaccine development, while the baboon model exhibits greater disease progression, making it suitable for evaluating anti-viral therapeutics and co-morbidities.
The Phase 3 trial of Novavax's NVX-CoV2373 vaccine is being conducted in the US and Mexico, enrolling up to 30,000 adults in two cohorts. The trial aims to evaluate the safety and efficacy of the vaccine candidate, which has shown promise in animal tests.
Researchers at the University of Zurich have developed a genetic engineering method to prevent Toxoplasma gondii parasite production, which causes toxoplasmosis. The new technique uses CRISPR-Cas9 gene editing scissors to switch off essential genes responsible for oocyst formation without leaving unwanted traces.
The Advanced Photon Source (APS) has been instrumental in the development of COVID-19 vaccines, allowing for rapid progress through genetic mutations that increase effectiveness. Scientists used APS ultrabright X-ray beams to illuminate virus structures and design vaccine techniques, drugs, and treatments.
Researchers achieved rapid development of effective vaccines against COVID-19, highlighting the collaboration between scientists and governments. However, this unprecedented speed revealed alarming fissures between science and policy makers.
The COVID-19 vaccine candidate, KBP-COVID-19, has demonstrated potential advantages in production speed and stability at room temperature, which could reduce the time between virus identification and vaccine deployment. The Phase I study will enroll 180 healthy volunteers to assess the safety and efficacy of the vaccine.
Researchers at the Ragon Institute have developed a new one-step CRISPR technique to rapidly create mice capable of producing human antibodies. The method dramatically shortens the timeline for generating specialized mice, allowing scientists to accelerate their research and respond more quickly to new developments in the field.
A survey of 788 US adults found that concerns about side effects were a significant barrier to getting the vaccine. Disparities in willingness to get vaccinated also existed among demographic groups, with younger and white respondents more likely to be willing than older and Black respondents.
A new iGIST method detects pertussis toxin levels, reducing animal testing. The method is more effective and enables detection of lower toxin levels than current methods.
A KU Leuven vaccine candidate, RegaVax, has shown promise in protecting against Covid-19 and yellow fever in hamsters and monkeys. The vaccine works after a single dose and offers long-lasting immunity to Covid-19.
The 2020 Golden Goose Award winners made significant breakthroughs in COVID-19 vaccine development, leveraging existing knowledge of coronaviruses and the human immune system. Their research has led to several vaccine candidates currently in Phase 3 clinical trials for effectiveness in preventing COVID-19 infection.
A DNA-based vaccine candidate has been found to be effective in protecting cynomolgus macaques from the Crimean-Congo hemorrhagic fever virus. The vaccine generated protective antibodies and prevented signs of disease in infected animals, offering a promising potential treatment for human patients.
A new microneedle skin patch has been developed by UConn researchers to provide immunization against infectious diseases through a single administration. The patch triggers a high immune response and offers a long-term protection similar to multiple injections.
The article emphasizes the importance of conducting rigorous evaluation to ensure COVID-19 vaccine safety and efficacy. Historical experience with vaccine development informs regulatory practices, including pre-licensure monitoring for rare adverse events and post-licensure pauses if serious adverse events are detected.
A study using a nonhuman primate model identified key features of SARS-CoV-2 causing COVID-19, including immunosuppressive effects. The research team also observed rapid viral multiplication in the upper and lower respiratory tracts, followed by a decrease in viral load.
Researchers evaluated all new COVID-19 vaccines approved by FDA over last decade, analyzing premarket development time, clinical evidence, and safety database size. The study found that vaccine approvals took an average of 10 months, with varying levels of evidence and follow-up durations.
Researchers warn that SARS-CoV-2 may develop resistance to COVID-19 vaccines, rendering them ineffective. To mitigate this risk, the team recommends using blood and nasal swab samples to assess vaccine efficacy and monitor for emerging resistance.
A new study suggests that combining T cell activation with antibody production could lead to longer-term protection against Zika virus. Researchers found that inducing CD8+ T cells was key in preventing Zika infection in mice, offering a promising approach for developing effective vaccines.
A Duke Health-led research team has identified a key marker that will help speed effective vaccine designs for cytomegalovirus (CMV). The finding provides an immune surrogate to test the effectiveness of vaccine candidates, which could aid in vaccine evaluation and predict potential efficacy.
Researchers have identified seven distinct groups of symptoms in mild COVID-19, including flu-like symptoms, joint pain, and loss of smell and taste. These findings suggest that the disease leaves behind significant changes in the immune system, even after recovery, and could inform the development of more effective vaccines.
McGill University professors have created an online COVID-19 vaccine tracker providing real-time updates on vaccine progress and characteristics. The tracker helps manage expectations about vaccine availability and promotes transparency in the regulatory process.
Researchers found that newborns' immune systems activate soon after birth and increase key factors of innate immunity, including the complement system. This development is critical for protecting against pathogens in infancy, where infections are prevalent.
Dr. Penny M. Heaton is honored with the PIDS Distinguished Research Award for her outstanding contributions to vaccine clinical research and development. She leads efforts at the Bill & Melinda Gates Medical Research Institute, optimizing therapeutics, vaccines, and monoclonal antibody candidates.
A global survey of 13,400 people in 19 countries found that 72% would likely take the vaccine, while 14% refused and 14% hesitated. Vaccine confidence was higher in countries with higher trust in government.
A new study by Cornell researchers found that COVID-19 vaccine efficacy is a key factor in Americans' willingness to adopt the vaccine, with increased effectiveness leading to higher acceptance rates. The study also highlighted the impact of political endorsements and geopolitical factors on vaccine uptake.
The COVID PROFILE study aims to investigate the immune response to COVID-19, understanding how long protection lasts and predicting reinfection. Researchers will follow participants for 12 months with regular blood samples and nose and throat swabs.
A recent study has found that potential COVID-19 vaccines are not affected by the dominant 'G-strain' of the virus. The G-strain now accounts for about 85 per cent of published SARS-CoV-2 genomes, but vaccine candidates targeting the spike protein remain effective. This discovery is good news for the hundreds of vaccines in development...
The Vaccination Game, developed by University of Oxford researchers, challenges players to deploy limited doses of a virtual vaccine to control the spread of a disease modelled on influenza. By replaying the game, players can improve their strategy and save more lives.
A team of scientists has developed a unique COVID-19 vaccine that utilizes a bovine adenovirus as a safe and effective delivery vehicle. The vaccine aims to provide protection to all segments of the population, especially older adults with declining immune systems.
A survey of 28 experts in vaccinology predicts that a publicly available COVID-19 vaccine may not be available before the fall of 2021. The majority of experts believe that the best-case scenario is a vaccine becoming available next summer, with some predicting it may take until 2022.
A West Virginia University professor argues that effective communication is crucial for gaining the American public's trust in scientists. By considering four dimensions of trust and tailored communication objectives, science communicators can increase perceptions of competence, integrity, benevolence, and openness.
A new CRISPR vaccine has been successfully tested in animal studies, providing protection against the parasitic skin disease leishmaniasis. The vaccine uses a modified version of the parasite that causes the disease, which induces immunity without causing clinical disease.
The University of Montana has received a five-year, $33.4 million award from the National Institutes of Health to develop and conduct clinical trials for opioid vaccines. The UM vaccine research team will advance lead opioid vaccine candidates to Phase I human clinical trials with funding from the NIH HEAL Initiative.
A new study confirms the safety and immunogenicity of the Vi-DT conjugate vaccine in children aged 6-23 months. The single-dose regimen shows anti-Vi seroconversion rates similar to the two-dose schedule, offering a promising solution for increasing global vaccination stockpiles.
Researchers developed a polymer-nanoparticle hydrogel that allows sustained release of vaccine components, increasing potency and duration of immune responses in mice. The hydrogel boosts antibody production with a 1,000-fold higher affinity for antigens.
Researchers have developed a tool called COVID-3D to monitor mutations in the COVID-19 virus, helping to inform vaccine and drug development. The tool uses genomic and protein information to aid researchers in identifying effective targets for new treatments.
Researchers at West Virginia University are developing a vaccine to prevent Lyme disease, which affects over 300,000 Americans annually. The team aims to identify relevant antigens and target them in hopes of clearing the pathogen out, making it harder for it to change and evade the immune system.
The International Vaccine Institute (IVI) is preparing clinical trial sites for COVID-19 vaccine efficacy trials in four African and Asian countries with the support of the Bill & Melinda Gates Foundation. IVI aims to bolster in-country capacity by 4Q2020 to ensure these sites are prepared for efficacy trials.
A study of over 27,000 COVID-19 samples reveals low genetic variation in SARS-CoV-2, suggesting a single vaccine could combat global infections. This finding supports the development of a broadly protective vaccine against COVID-19, building on previous successes with other viruses.